Lisinopril/amlodipine
 Lisinopril (top) and amlodipine (bottom) | |
| Combination of | |
|---|---|
| Lisinopril | ACE inhibitor |
| Amlodipine | Calcium channel blocker |
| Clinical data | |
| Trade names | Lisonorm, Dironorm, others |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| (verify) | |
Lisinopril/amlodipine, sold under the brand name Lisonorm among others, is a medication used to treat
high blood pressure.[1] It is a combination of lisinopril an ACE inhibitor with amlodipine a calcium channel blocker.[1] It may be used when blood pressure is not well controlled with each of the two agents alone.[4] It is taken by mouth.[1]
Side effects may include
angiotensin II and increasing bradykinin while amlodipine decreases the entry of calcium into the muscle cells in the heart and blood cells.[4]
The combination was approved for medical use in the European Union in 2008.[1] The combination on the World Health Organization's List of Essential Medicines.[5][6] While it is available in India and the European Union it is not available in Canada, Australia, or the United States as of 2019.[7]
Pharmacology
Lisinopril/amlodipine is a combination of two agents which both act to induce vascular smooth muscle relaxation to lower blood pressure in distinct ways:[1]
- Lisinopril inhibits angiotensin converting enzyme (ACE), the enzyme responsible for converting angiotensin I into angiotensin II (a vasoconstrictor).
- Amlodipine inhibits influx of calcium into smooth muscle cells through calcium channels thereby inhibiting Ca-dependent contraction.
References
- ^ a b c d e f "Lisonorm". European Medicines Agency. Archived from the original on 24 March 2020. Retrieved 30 October 2019.
- ^ "Archived copy" (PDF). Archived (PDF) from the original on 2022-09-06. Retrieved 2022-09-06.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Archived copy" (PDF). Archived (PDF) from the original on 2022-09-06. Retrieved 2022-09-06.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ a b c d e "Summary of Product Characteritics" (PDF). EMA. Archived (PDF) from the original on 30 October 2019. Retrieved 15 November 2019.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "An application to include blood pressure lowering drug fixed dose combinations to the model list of essential medicines lists for the treatment of essential hypertension in adults" (PDF). WHO. p. 33. Archived (PDF) from the original on 24 March 2020. Retrieved 15 November 2019.
